"Turpentine VC" | Venture Capital and Investing
E52: Charting the Course of Biotech with Laura Deming, GP of Longevity Fund, and Will Eden of Sylvan Consulting
Aug 20, 2024
Laura Deming, a General Partner at Longevity Fund, and Will Eden from Sylvan Consulting delve into the fascinating world of biotech investments. They explore the evolution of longevity research and groundbreaking technologies like cell and gene therapies. The duo discusses the FDA's complex role in regulating innovations and the challenges faced by biotech startups. They also highlight the dramatic growth in the longevity sector since 2011 and ponder bold aspirations like biological immortality, making the conversation both insightful and entertaining.
01:22:40
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The evolving biotech investment landscape now prioritizes preclinical investments across diverse therapeutic segments, including antibodies and cell therapies.
- Digital health technologies have distinct challenges in FDA approval processes, focusing more on wellness than serious medical interventions like cancer treatments.
Deep dives
Evolving Landscape of Biotech Investments
The biotech investment landscape has undergone significant changes since the early days of companies like Genentech. Investors have shifted focus to areas including seed stages and early clinical companies, with an emphasis on preclinical investments. Various segments within biotech can be categorized based on their therapeutic areas, such as antibodies, RNA, and cell therapies, as well as pharmaceuticals, med devices, and tools and services. By understanding the unique complexities of these segments, investors can make informed decisions on where to allocate resources.
